Serologicals disclosed its plan to buy it in March and said it would close last month.
Privately held LINCO comprises LINCO Research and LINCO Diagnostic Services. LRI sells multiplex, ELISA and RIA immunoassay products and technologies, and LDS provides bioanalytical contract services supporting research and drug development. The company is based in St. Louis.
As expected, Serologicals paid $64.5 million in cash for the stock of LINCO plus $10.3 million for the land and buildings the company occupies.
Last week, Millipore said it plans to pay $1.4 billion to acquire Serologicals.